Nifty
Sensex
:
:
8139.30
27946.93
-114.50 (-1.39%)
-318.38 (-1.13%)

Pharmaceuticals & Drugs

Rating :
71/99  (View)

BSE: 500257 | NSE: LUPIN

595.75
16.70 (2.88%)
03-Apr-2020 | 10:09AM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  582.45
  •  601.35
  •  578.00
  •  579.05
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  719369
  •  4285.64
  •  884.00
  •  504.75

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 26,237.65
  • N/A
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 33,746.60
  • 0.86%
  • 2.06

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.93%
  • 0.98%
  • 10.92%
  • FII
  • DII
  • Others
  • 24.66%
  • 14.16%
  • 2.35%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.13
  • 5.54
  • -1.50

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.35
  • -4.45
  • -8.50

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -1.32
  • -24.16
  • -38.16

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 26.53
  • 29.03
  • 24.02

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.34
  • 4.59
  • 2.85

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.67
  • 15.71
  • 12.84

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Net Sales
3,769
3,947
-5%
4,360
3,951
10%
4,418
3,856
15%
4,406
4,034
9%
Expenses
3,340
3,266
2%
3,629
3,401
7%
3,558
3,329
7%
3,534
3,325
6%
EBITDA
429
682
-37%
731
550
33%
860
527
63%
872
709
23%
EBIDTM
11%
17%
17%
14%
19%
14%
20%
18%
Other Income
94
40
133%
133
231
-42%
72
184
-61%
86
145
-40%
Interest
89
78
13%
86
74
17%
86
69
25%
86
59
46%
Depreciation
253
219
16%
321
265
21%
317
259
22%
281
273
3%
PBT
-108
82
-
-90
441
-
530
383
38%
595
-942
-
Tax
767
245
213%
34
173
-80%
228
181
26%
300
-163
-
PAT
-875
-163
-
-124
268
-
302
202
49%
295
-779
-
PATM
-23%
-4%
-3%
7%
7%
5%
7%
-19%
EPS
-18.44
-3.35
-
-2.81
5.88
-
6.70
4.48
50%
6.40
-17.33
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
16,954
16,718
15,804
17,494
14,256
12,770
11,287
9,641
7,083
5,819
4,871
Net Sales Growth
7%
6%
-10%
23%
12%
13%
17%
36%
22%
19%
 
Cost Of Goods Sold
5,844
5,235
4,734
4,661
4,010
3,806
3,486
3,222
2,365
2,061
1,821
Gross Profit
11,109
11,484
11,070
12,833
10,245
8,964
7,801
6,420
4,718
3,758
3,050
GP Margin
66%
69%
70%
73%
72%
70%
69%
67%
67%
65%
63%
Total Expenditure
14,061
13,836
12,657
13,001
10,570
9,150
8,284
7,371
5,638
4,641
3,887
Power & Fuel Cost
-
476
434
378
381
363
334
320
269
205
155
% Of Sales
-
3%
3%
2%
3%
3%
3%
3%
4%
4%
3%
Employee Cost
-
3,151
2,865
2,850
2,142
1,747
1,465
1,267
970
768
550
% Of Sales
-
19%
18%
16%
15%
14%
13%
13%
14%
13%
11%
Manufacturing Exp.
-
2,030
2,088
2,270
1,766
1,321
1,130
977
753
604
500
% Of Sales
-
12%
13%
13%
12%
10%
10%
10%
11%
10%
10%
General & Admin Exp.
-
1,429
1,220
1,306
1,196
807
811
692
471
325
292
% Of Sales
-
9%
8%
7%
8%
6%
7%
7%
7%
6%
6%
Selling & Distn. Exp.
-
1,299
1,151
1,253
870
835
775
710
648
547
447
% Of Sales
-
8%
7%
7%
6%
7%
7%
7%
9%
9%
9%
Miscellaneous Exp.
-
216
166
284
205
271
284
185
163
131
447
% Of Sales
-
1%
1%
2%
1%
2%
3%
2%
2%
2%
2%
EBITDA
2,893
2,882
3,148
4,493
3,685
3,620
3,003
2,270
1,445
1,178
984
EBITDA Margin
17%
17%
20%
26%
26%
28%
27%
24%
20%
20%
20%
Other Income
386
364
150
107
185
240
116
28
14
22
14
Interest
346
308
204
153
59
10
27
41
35
34
38
Depreciation
1,173
1,085
1,086
912
487
435
261
332
228
171
124
PBT
927
1,853
2,008
3,535
3,324
3,415
2,832
1,925
1,196
994
836
Tax
1,329
902
288
979
1,059
970
962
584
309
115
136
Tax Rate
143%
60%
53%
28%
32%
28%
34%
30%
26%
12%
16%
PAT
-403
603
248
2,549
2,256
2,403
1,836
1,314
868
865
689
PAT before Minority Interest
-404
612
255
2,556
2,265
2,444
1,870
1,340
888
879
700
Minority Interest
-1
-9
-7
-7
-9
-41
-33
-26
-20
-15
-11
PAT Margin
-2%
4%
2%
15%
16%
19%
16%
14%
12%
15%
14%
PAT Growth
0%
143%
-90%
13%
-6%
31%
40%
51%
0%
26%
 
Unadjusted EPS
-8.15
13.41
5.56
56.69
50.25
53.54
40.99
29.39
19.43
19.36
15.84

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
13,742
13,577
13,498
11,163
8,874
6,932
5,204
4,013
3,281
2,568
Share Capital
90
90
90
90
90
90
90
89
89
89
Total Reserves
13,433
13,275
13,234
10,959
8,728
6,816
5,108
3,921
3,191
2,478
Non-Current Liabilities
7,296
6,876
6,447
6,032
426
507
573
730
534
1,283
Secured Loans
359
448
217
6
12
24
38
28
54
872
Unsecured Loans
6,283
5,976
5,431
5,368
89
127
209
405
245
268
Long Term Provisions
371
357
309
190
162
132
112
77
37
0
Current Liabilities
6,130
5,096
6,121
5,061
3,729
2,630
3,007
3,120
2,507
1,189
Trade Payables
2,498
2,575
2,589
1,989
1,956
1,594
1,543
1,379
993
884
Other Current Liabilities
1,280
1,517
658
1,001
830
288
381
377
201
83
Short Term Borrowings
1,580
452
2,304
1,745
369
402
727
1,047
791
0
Short Term Provisions
772
551
569
326
574
345
356
317
522
223
Total Liabilities
27,215
25,589
26,100
22,289
13,054
10,135
8,843
7,935
6,374
5,066
Net Block
11,087
10,362
11,033
8,717
4,368
3,356
3,000
2,750
2,057
1,906
Gross Block
15,732
13,860
12,395
9,212
6,645
5,284
4,684
4,192
2,964
2,613
Accumulated Depreciation
4,645
3,498
1,362
495
2,276
1,928
1,684
1,442
908
707
Non Current Assets
13,362
13,379
14,147
12,402
5,221
4,035
3,700
3,593
2,869
2,290
Capital Work in Progress
1,640
2,598
2,133
2,702
552
286
311
435
478
349
Non Current Investment
186
27
22
14
3
2
2
3
3
26
Long Term Loans & Adv.
403
383
951
960
274
373
387
397
314
0
Other Non Current Assets
47
9
8
8
0
0
0
0
5
0
Current Assets
13,854
12,210
11,953
9,887
7,832
6,100
5,143
4,342
3,504
2,775
Current Investments
2,110
235
2,114
2
1,656
176
0
0
0
0
Inventories
3,837
3,662
3,642
3,274
2,504
2,129
1,949
1,733
1,200
971
Sundry Debtors
5,150
5,192
4,307
4,549
2,657
2,464
2,187
1,780
1,256
1,127
Cash & Bank
987
1,408
698
822
481
798
435
402
420
202
Other Current Assets
1,770
621
533
479
535
533
572
427
628
476
Short Term Loans & Adv.
992
1,091
658
762
295
275
340
306
516
476
Net Current Assets
7,724
7,114
5,832
4,826
4,103
3,471
2,136
1,222
997
1,586
Total Assets
27,215
25,589
26,100
22,289
13,054
10,135
8,843
7,935
6,374
5,066

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
1,666
1,751
4,114
-382
2,733
2,004
1,251
560
798
676
PBT
1,517
547
3,543
3,329
3,415
2,832
1,925
1,196
994
836
Adjustment
1,588
2,782
1,215
585
357
410
420
259
207
144
Changes in Working Capital
-500
-1,019
505
-3,126
-95
-466
-549
-581
-160
-137
Cash after chg. in Working capital
2,605
2,310
5,262
788
3,677
2,776
1,795
874
1,042
843
Interest Paid
0
0
0
0
0
0
0
0
0
0
Tax Paid
-939
-558
-1,149
-1,170
-944
-772
-544
-314
-244
-167
Other Direct Exp. Paid
0
0
0
0
0
0
0
0
0
0
Extra & Other Items
0
0
0
0
0
0
0
0
0
0
Cash From Investing Activity
-3,282
470
-2,527
-6,962
-1,055
-859
-522
-741
-520
-680
Net Fixed Assets
-463
-1,394
-876
481
-416
-309
-325
-390
-558
-310
Net Investments
-2,026
1,551
-3,173
-297
-2,281
-476
-1
-6
43
-250
Others
-794
313
1,522
-7,146
1,643
-74
-196
-345
-5
-120
Cash from Financing Activity
744
-1,492
433
5,836
-197
-857
-663
109
-163
136
Net Cash Inflow / Outflow
-872
729
2,019
-1,508
1,482
288
66
-72
116
132
Opening Cash & Equivalents
1,416
687
780
2,095
607
311
245
296
164
68
Closing Cash & Equivalent
544
1,416
2,799
780
2,108
607
311
245
296
198

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
299
296
295
245
196
154
116
90
74
58
ROA
2%
1%
11%
13%
21%
20%
16%
12%
15%
15%
ROE
5%
2%
21%
23%
31%
31%
29%
24%
30%
35%
ROCE
8%
4%
19%
24%
40%
41%
33%
24%
25%
28%
Fixed Asset Turnover
2
2
2
2
2
2
2
2
2
2
Receivable days
65
64
92
92
73
75
75
78
74
76
Inventory Days
47
49
72
74
66
65
69
75
68
72
Payable days
59
69
60
63
64
64
64
64
61
64
Cash Conversion Cycle
54
44
105
103
74
76
80
89
80
84
Total Debt/Equity
1
1
1
1
0
0
0
0
0
0
Interest Cover
6
4
24
57
349
107
48
35
30
23

News Update


  • Lupin gets EIR from USFDA for Inhalation Research Center in Florida
    30th Mar 2020, 11:21 AM

    The facility was inspected by the USFDA, between February 19, 2020 and February 26, 2020

    Read More
  • Lupin, Mylan announce positive CHMP opinion for Nepexto, Biosimilar Etanercept
    28th Mar 2020, 10:27 AM

    The positive CHMP opinion is based on a biosimilarity assessment which included preclinical and clinical studies demonstrating bioequivalence to the reference product

    Read More
  • Lupin launches Betamethasone Dipropionate Ointment USP
    21st Mar 2020, 09:51 AM

    The product would be manufactured at Lupin's Pithampur -Unit III facility, India

    Read More
  • Lupin receives International Sustainability Rating System Certification
    12th Mar 2020, 12:49 PM

    The certification was received after audits were conducted at four of the company's manufacturing facilities

    Read More
  • Lupin wins coveted India Pharma Leader Award
    11th Mar 2020, 11:42 AM

    The company has won the award at the India Pharma 2020 and India Medical Device 2020 conference

    Read More
  • Lupin launches authorized generic version of Vimovo
    5th Mar 2020, 16:45 PM

    Naproxen and Esomeprazole Magnesium delayed-release tablets had an annual sales of approximately $400 million in the US

    Read More
  • Lupin launches Ethacrynic Acid Tablets
    25th Feb 2020, 15:23 PM

    The product would be manufactured at Lupin's Nagpur OSD facility, India

    Read More
  • USFDA completes inspection of Lupin’s Aurangabad facility
    17th Feb 2020, 10:18 AM

    The inspection concluded without any observation

    Read More
  • Lupin launches Moxifloxacin Ophthalmic Solution
    14th Feb 2020, 16:37 PM

    The product would be manufactured at Lupin's Pithampur Unit II facility, India

    Read More
  • USFDA completes inspection of Lupin’s Pithampur facility
    12th Feb 2020, 15:12 PM

    The inspection for the Pithampur unit-1 facility closed with two 483 observations

    Read More
  • Lupin gets nod for Leflunomide Tablets
    6th Feb 2020, 09:06 AM

    The product would be manufactured at Lupin's Pithampur facility, India

    Read More
  • MHRA completes inspection at Lupin’s three manufacturing units in Pithampur
    27th Jan 2020, 09:55 AM

    The inspection for the three units at Pithampur closed with no critical observation and one major observation

    Read More
  • Lupin’s CSR arm wins Corporate Citizen award 2019
    21st Jan 2020, 10:37 AM

    The company was conferred this award in the CSR category 'Initiative towards Agriculture,' for its beekeeping project

    Read More
  • Lupin, EAU conclude third edition of Masterclass ‘Best of EAU19’
    20th Jan 2020, 10:11 AM

    It also marked the second consecutive year of Lupin’s collaboration with the EAU for organising the Masterclass

    Read More
  • USFDA completes inspection of Lupin’s Vizag API manufacturing facility
    18th Jan 2020, 11:01 AM

    The inspection was carried out between January 13, 2020 and January 17, 2020

    Read More
  • Lupin's Ankleshwar facility wins Par Excellence award
    13th Jan 2020, 10:16 AM

    The company’s nomination summarised its transformation project to improve the yield and quality of Cefadroxil products

    Read More
  • USFDA completes inspection of Lupin’s Nagpur facility
    13th Jan 2020, 09:47 AM

    The inspection closed with two 483 observations

    Read More
  • USFDA classifies inspection of Lupin’s Tarapur facility as OAI
    13th Jan 2020, 09:36 AM

    The inspection at the Toropur facility had closed with three observations

    Read More
  • Lupin's Ankleshwar facility wins gold award from American Society for Quality
    3rd Jan 2020, 10:20 AM

    This is the fourth consecutive year that Lupin's Ankleshwar facility has won the Gold Award from the American Society for Quality

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.